.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
As immunotherapy transforms oncology, intensivists face severe immune-mediated adverse events. This comprehensive review outlines critical care protocols for managing cytokine release syndrome, immune effector cell-associated neurotoxicity, and organ-specific toxicities in critically ill cancer patients.
The Maharashtra cabinet has cleared the Rs 4,250 crore PRAGATI project, co-funded by ADB, to construct and upgrade district hospitals, expand clinical care for chronic non-communicable diseases, bolster cancer screening, and digitize regional healthcare services through modern telemedicine and electronic records.
Primary cutaneous ALCL with a TCR-gamma-delta phenotype and DUSP22-IRF4 rearrangement represents a rare diagnostic challenge. Identifying this indolent profile avoids misclassification as aggressive lymphoma and prevents unnecessary systemic cytotoxic chemotherapy in elderly patients.
Recent breakthroughs in cellular therapy and quadruplet regimens have transformed multiple myeloma treatment decisions. Clinicians now integrate cytogenetics, functional fitness, and measurable residual disease to individualize therapy across newly diagnosed, smoldering, and relapsed disease settings.
